Rheumatology

Sandoz Is 0-3 in Enbrel Patent Case

May 17th 2021

By Tony Hagen

Originator company Amgen has won another round in defending its lucrative etanercept franchise, but the decision is sure to intensify scrutiny of extended patent protections.

German Study Calculates Adalimumab Biosimilar Savings From Earlier Intervention

May 17th 2021

By Tony Hagen

Investigators evaluated both biosimilar vs originator savings and savings from earlier use of a lower-cost adalimumab biosimilar (Amgevita).

Alvotech Files Suit to Invalidate Humira Patents

May 11th 2021

By Tony Hagen

After being sued for allegedly stealing adalimumab process information, Alvotech fires back.

Inflectra Stands Out in Meta-analysis of Agents for Crohn Disease

May 11th 2021

By Deana Ferreri, PhD

Investigators ranked biologics and Janus kinase 1 inhibitors based on past findings.

Regulators Look Back on 15 Years of Biosimilars in Europe

May 7th 2021

By Tony Hagen

Advances in analytical testing have improved confidence in biosimilars, according to a Medicines for Europe panel.

The Difference Between an Interchangeable Biosimilar and One That Isn't

May 5th 2021

By Tony Hagen

The anatomy of an interchangeability switching study.

Amgen Canada Launches Adalimumab Biosimilar

May 4th 2021

Amgevita is now broadly available across Canada.

AbbVie CEO Is on Deck as Antitrust Hearings Heat Up

May 3rd 2021

By Tony Hagen

Representative Carolyn B. Maloney, D-New York, questions the use of pharmaceutical profits to defend against biosimilar competition.

Reports From Biocon, Celltrion on Finances, COVID-19 Treatments

May 1st 2021

By Tony Hagen

Biocon tests the waters with itolizumab in pandemic-ravaged India, and Celltrion announces early success with an agent for the South African variant.

Amgen, Merck, Teva Provide First-Quarter Biosimilars Info

April 30th 2021

By Tony Hagen

There's no end in sight for Enbrel (etanercept) sales erosion, but Amgen's biosimilars are holding their own, the company reported.